; charset=UTF-8 Pharmalot Big Pension Fund To Fight Lilly Over Directors Posted: 28 Mar 2008 10:38 AM CDT The California Public Employees Retirement System, better known as Calpers, plans to withhold votes for three of the drugmakers directors who are up for reelection next month over the stock price and poor corporate governance. Among the directors is John Lechleiter, who becomes ceo next week and has been on the board for the past three years. It was on their watch that Eli Lilly experienced severe stock poor corporate governance practices, and was unresponsive to shareowners, Russell Read, Calpers chief investment officer, says in a statement. The pension fundБ=80=99s wrote a letter to shareholders saying that, as of Feb. 29, 2008, LillyБ=80=99s stock had significantly underperformed both the SP 500 and the SP 500 Health Care Index. The drugmaker, the fund continued, trailed index peers by 16.7 percent over three years, by 35.5 percent for five years, and by 55.7 percent over the past 10 years, while losing 6.5 percent the past decade on a total return basis. Calpers owns about 4.7 million shares in Lilly, which has about 1.14 billion shares outstanding. (more) Will Investors Need A Pill For Uncontrollable Crying? Posted: 28 Mar 2008 08:17 AM CDT Anyone familiar with involuntary emotional expression disorder? This is another way of saying uncontrollable laughing or crying, and a little drugmaker called Avanir Pharmaceuticals hopes to market a pill for this distinct neurological disorder. Also known as pseudobulbar affect, the affliction has gotten talked up in recent years and investors are buying into the concept. Earlier this week, Avanir received commitments for $40 million in funding from a group of venture capital firms, including ProQuest Investments, whose scientific advisors include Howard Scher, a noted oncologist caught up in the scandal engulfing the FDA over the Provenge prostate-cancer vaccine. The proceeds will be used to complete a Phase III test of its Zenvia pill, which used to be called Neurodex. Is there a market for such a pill? Avanir has spent considerable effort ensuring one exists. As noted by The New York Times three years ago, the drugmaker recruited neurologists and psychiatrists as scientific advisersto prime the market by elevating an ill-defined group of symptoms into a conditionin hopes of establishing awareness of it among doctors and patients. The paper also wrote some critics say the condition may not require meds in people who are fighting more serious health problems, and the syndrome actually has various names and possible treatments. So there may be some irony in all this: if Zenvia is approved by the FDA, investors may need the pill themselves as they laugh all the way to the proverbial bank. And for those who complain about endless disease mongering, perhaps Zenvia will relieve their undying grief. The Vytorin Data At The ACC: No Smoking Gun? Posted: 28 Mar 2008 07:34 AM CDT Thats what one Wall Street analyst posits this morning in an investor note. As you may know, the complete Enhance trial - that controversial study of Vytorin - will be unveiled and dissected at the American College of Cardiology conference on Sunday. The lead investigator, John Kastelein, will make his first public remarks since the release of preliminary data in January engulfed Schering-Plough and Merck in controversy and embarassment. The results found that the cholesterol pill failed to show any benefit over the much cheaper Zocor in reducing plaque in the carotid artery, and even showed a statistically insignificant buildup, although it did a better job of lowering LDL. A debate then ensued about the merits of using Vyotrin, which includes Zetia and MerckБ=80=99s Zocor. But does the full study, which will be released on Sunday by The New England Journal of Medicine, contain still more damaging info? Probably not, writes Tim Anderson of Sanford Bernstein, the results will very likely contain no smoking gun on either primary or secondary endpoints. We think the prevailing opinion will be that the trial showed what it did - no difference in artery wall thickening between the two treatment arms - due to the fact that trial participants had surprisingly healthy arteries to begin with. (And this was) probably related to intense pre-treatment with cholesterol reducers prior to enrolling in Enhance, making it difficult to show a difference between the two arms of the trial. (more) Drugmakers Spend Lavishly On Docs Down Under Posted: 28 Mar 2008 07:15 AM CDT Australian drug companies forked out more than $30 million in six months hosting doctors at controversial educational events, The Sydney Morning Herald reports. Medicines Australia, the industry trade group, has been forced to detail spending on doctor seminars of up to $2,500 a head, often hosted at expensive hotels and in exotic locations. A report prepared for Medicines Australia by international consulting firm Deloitte shows that 42 companies spent $31 million, including $16.4 million on direct hospitality costs like meals, flights and hotels, in the second half of last year. In one case, AstraZeneca paid $514,000 to host a national symposium for 226 in Melbourne - a cost of $2,275 a head. There were 385,221 attendances by doctors at 14,643 functions over the period. Of these, 52 unidentified events are now under investigation for possible breaches of the industrys new strict code of conduct, imposed by the Australian Competition and Consumer Commission to improve transparency. Want to see which drugmaker spent how much? Look at the list. (more) Trial Of Former Bristol-Myers CFO Is Delayed Posted: 28 Mar 2008 06:34 AM CDT Frederick Schiff, who faces two felony counts of conspiracy and securities fraud for his role in an alleged channel stuffing scheme to inflate the drugmakers earnings between 2002 and 2002, just got his second break in as many weeks. You may recall that last week, US District Court Judge Faith Hochberg issued a ruling that scaled back the federal case. And so the US Attorney in Newark, NJ, Christopher Christie, has decided to appeal, which will cause an unspecified delay, The New York Times reports. In a ruling dated March 19, Judge Faith Hochberg sided with Schiff and limiting the scope of what prosecutors can argue against him and criticizing them for repeatedly changing their theory of the crime they say he committed. Б=80=9CThe court will permit no further Б=80=98legal theory morphsБ=80=99 in this case,Б=80=9D the judge said, noting that the charges against Schiff had been lingering for three years, the paper writes. One part of her order prevents the prosecution from linking SchiffБ=80=99s activities to a plunge in the price of Bristol-Myers Squibb stock during 2002, after inventory problems were disclosed. The prosecutors had hoped to use that approach to tie SchiffБ=80=99s actions to investor losses. Meanwhile, the case against Rick Lane, the former Bristol-Myers pharma head, will remain in limbo since the cases are being tried separately. (more) New Antipsychotics No Better For First Episodes Posted: 28 Mar 2008 06:23 AM CDT The so-called atypicals - including Abilify, Risperdal, Zyprexa, Seroquel and Geodon - have been hailed as more effective and easier to tolerate than the older and cheaper kind such as Haldol, which cause tremors and rigid muscles. But the new generation are no better at treating a first episode of schizophrenia, according to a study in The Lancet. Such findings are important because the atypicals are heavily promoted, widely prescribed and expensive. The Dutch researchers studied 498 patients between 18 and 40 years old in Europe and Israel in an open trial lasting 12 months. The patients were randomly assigned to a low-dose version of Haldol, or a higher dose of one of four atypicals. They found that during the subsequent 12-month period, more patients taking Haldol discontinued treatment when compared with patients taking the other drugs. However, the reductions in all symptoms were about the same for all groups. But when the researchers further analyzed the data according to sex, tendencies towards suicide, and substance abuse, they found no significant differences between the drugs. Despite a high continuation rate for several of the atypicals, the researchers wrote that it cannot be concluded that antipsychotic drugs are more efficacious in the treatment of these patients. As an aside, many of the authors reported various ties to the drugmakers that sell atypicals. And funding for the study was provided by AstraZeneca, Pfizer and Sanofi-Aventis. Up And Down The Ladder Job Changes Posted: 28 Mar 2008 06:13 AM CDT Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and weБ=80=99ll share with it others. ThatБ=80=99s right. Send us your announcements and weБ=80=99ll find a home for them. DonБ=80=99t be shy. Everyone wants to know who is coming and going, especially with all the layoffs being announced each month. Despite downsizing, there is movement. Here are some of the latest changes. Recognize anyone? Depomed hired Abid Rawn as vp sales and marketing; Regeneron promoted Joanne Deyo to vp facilities; EKR Therapeutics named Richard DeSimone as COO; EKR Therapeutics hired Ernic Biczak as senior vp marketing; EKR Therapeutics hired Dave Iwanicki as senior vp commercial operations; EKR Therapeutics hired Stephen Hulse as vp sales; EKR Therapeutics promoted Tong Zhang to vp business development; Cornerstone BioPharma named George Esgro vp sales and marketing; Xencor appointed David King as chairman; BioMarin Pharma hired Steve Glass as vp and general mgr of European operations; Zelos Therapeutics named David Krause as senior vp RD and chief medical officer; Biovitrium hired Peter Edman as chief scientific officer from AstraZeneca, where he was vp global development; MPM Capital hired Robert Millman as chief IP counsel from Alnylam MPM Capital also hired Elizabeth Stoner from Merck Research Labs; Takeda named Alan MacKenzie as ceo of Takeda Pharma North America; Takeda also named Nancy Joseph-Ridge as president of Takeda global RD center; Barr Labs named Christine Mundkur chief exec of the generic unit; Barr Labs also named G. Frederick Wilson chief exec of the Duramed unit; Barr Labs named Mike Bogda president and COO; And Barr Labs named Tim Sawyer exec vp of global generic sales and marketing. Pharmalot Pharmalittle Its Friday! Posted: 28 Mar 2008 06:10 AM CDT We are particularly happy, especially after our difficulties yesterday. You may have noticed sporadic posting, which was due to a burst pipe valve in the basement of the Pharmalot headquarters, a disruption assuaged only by our on-call Pharmalot maintenance crew. The problem has been solved, although we look forward to a respite. Nonetheless, there is much to do, especially as the American College of Cardiology conference kicks off and we prepare for a speaking engagement of our own. So grab that cup of stimulation and polish off the week with us Drug-Coated Stents No Riskier Than Others: Study (Dow Jones) Some Biotechs Race To Develop Biosimilars (Bloomberg News) JJ Foot Gel Poses Cancer Risk (Yahoo/Reuters) Takeda Scraps Development Of Cholesterol Pill (Bloomberg News) Wyeth And Trubion Halt Drug Study (The Seattle Skye Pharma Seeks Compromise On Its Bonds (The Financial Times*) * - subscription may be required Death Of A Sales Team? Wyeth Cuts 1,200 Reps Posted: 27 Mar 2008 08:00 PM CDT The positions are being eliminated as of Monday as part of a major companywide program announced two months ago to save money in the face of regulatory setbacks and generic competition. At the time, the drugmaker acknowledged plans to cut about 10 percent of its global workforce of 50,000 or so, and that sales reps were high on the list. Wyeth employs roughly 25,000 people in the US. A Wyeth spokesman tells the Associated Press that reps will be cut from both the pharma and consumer products divisions from around the US. etkus said they will get severance pay and continuing benefits. He would not say how many US sales reps Wyeth employs, although one source say the primary care sales force numbers fewer than 2,000. The drugmaker has been whittling away at its sales teams since 2005, when it cut about 20 percent of its reps and began using more part-timers. For now, the spokesman says the number of overall jobs to be shed as part of the ongoing reorganization may change. Were still evaluating the composition of our global work force, he told the AP. Our short-term objective is to achieve a reduction in force of 4 to 6 percent by the middle of the year. We are on track to achieve that. Last month, Wyeth won FDA approval to sell its Pristiq antidepressant, but the drugmaker has otherwise run into one setback after another in winning permission to market other drugs. Over the past year, the FDA has bounced a drug, demanded more data or a new patient study. Meanwhile, Wyeth expects generic competition for the Protonix heartburn med, one of its biggest sellers with sales of $1.9 billion. Japanese Drugmaker Pays $4M To Settle Fraud Posted: 27 Mar 2008 04:58 PM CDT Otsuka American Pharmaceutical, the US unit of the Japanese drugmaker, agreed to pay more than $4 million to resolve allegations that it marketed the Abilify antipsychotic for off-label uses, according to the US Department of Justice. The settlement resolves allegations that, from 2002 through 2005, Otsuka knowingly promoted the sale and use of Abilify for pediatric use and to treat psychosis, although at the time, the FDA had not approved the drug for use in geriatric patients, teenagers or children. Last November, the FDA did approve Abilify for teenagers. Otsuka developed Abilify in Japan and then entered an agreement with Bristol-Myers to co-promote the drug in the US. Bristol-Myers paid $515 million last September to settle the same allegations. Meanwhile, the whistleblower, Joseph Piacentile, a physician, will receive about $348,000 as his share of the federal recovery amount from the settlement, and an additional share of the state settlement amount. -- You are buy onlined to email updates from "Pharmalot." To stop receiving these emails, you may unsubcribe now If you prefer to purchase via postal mail, write to: Pharmalot, c/o FeedBurner, 549 W Randolph, Chicago IL USA 60661 This Email Delivery powered by FeedBurner. =09 ; charset=UTF-8 Pharmalot =09=09=09h1 a:hover ! important;} tr td div ul { =09=09=09} =09 tr td div blockquote { 6px solid #dadada; =09=09=09} =09 tr td div li { =09=09=09} tr td a:link, tr td a:visited, tr td a:active { =09=09=09}=09 =09=09=09img {border:none;} =09=09 Pharmalot Big Pension Fund To Fight Lilly Over Directors Posted: 28 Mar 2008 10:38 AM CDT The California Public Retirement System, better known as Calpers, plans to withhold votes for three of the directors who are up for reelection next month over the stock price and poor corporate governance. Among the directors is John Lechleiter, who becomes ceo next week and has been on the board for the past three years. “It was on their watch that Eli Lilly experienced severe stock poor corporate governance practices, and was unresponsive to Russell Read, Calpers’ chief investment officer, says in a statement. The pension fundБ=80=99s wrote a letter to shareholders saying that, as of Feb. 29, 2008, LillyБ=80=99s stock had significantly underperformed both the S&P 500 and the S&P 500 Health Care Index. The drugmaker, the fund continued, trailed index peers by 16.7 percent over three years, by 35.5 percent for five years, and by 55.7 percent over the past 10 years, while losing 6.5 percent the past decade on a total return basis. Calpers owns about 4.7 million shares in Lilly, which has about 1.14 billion shares outstanding. (more…) Will Investors Need A Pill For Uncontrollable Crying? Posted: 28 Mar 2008 08:17 AM CDT Anyone familiar with involuntary emotional expression disorder? This is another way of saying uncontrollable laughing or crying, and a little drugmaker called Avanir Pharmaceuticals hopes to market a pill for this “distinct neurological Also known as pseudobulbar affect, the affliction has gotten talked up in recent years and investors are buying into the concept. Earlier this week, Avanir received commitments for $40 million in funding from a group of venture capital firms, including ProQuest Investments, whose scientific advisors include Howard Scher, a noted oncologist caught up in the scandal engulfing the FDA over the Provenge prostate-cancer vaccine. The proceeds will be used to complete a Phase III test of its Zenvia pill, which used to be called Neurodex. Is there a market for such a pill? Avanir has spent considerable effort ensuring one exists. As noted by The New York Times three years ago, the drugmaker neurologists and psychiatrists as scientific prime the market by elevating an ill-defined group of symptoms into a hopes of establishing awareness of it among doctors and The paper also wrote some critics say the condition may not require meds in people who are fighting more serious health problems, and the syndrome actually has various names and possible treatments. So there may be some irony in all this: if Zenvia is approved by the FDA, investors may need the pill themselves as they laugh all the way to the proverbial bank. And for those who complain about endless disease mongering, perhaps Zenvia will relieve their undying grief. The Vytorin Data At The ACC: No Smoking Gun? Posted: 28 Mar 2008 07:34 AM CDT That’s what one Wall Street analyst posits this morning in an investor note. As you may know, the complete Enhance trial - that controversial study of Vytorin - will be unveiled and dissected at the American College of Cardiology conference on Sunday. The lead investigator, John Kastelein, will make his first public remarks since the release of preliminary data in January engulfed Schering-Plough and Merck in controversy and embarassment. The results found that the cholesterol pill failed to show any benefit over the much cheaper Zocor in reducing plaque in the carotid artery, and even showed a statistically insignificant buildup, although it did a better job of lowering LDL. A debate then ensued about the merits of using Vyotrin, which includes Zetia and MerckБ=80=99s Zocor. But does the full study, which will be released on Sunday by The New England Journal of Medicine, contain still more damaging info? Probably not, writes Tim Anderson of Sanford Bernstein, “the results will very likely contain no smoking gun” on either primary or secondary endpoints. “We think the prevailing opinion will be that the trial showed what it did - no difference in artery wall thickening between the two treatment arms - due to the fact that trial participants had surprisingly healthy arteries to begin with. (And this was) probably related to intense pre-treatment with cholesterol reducers prior to enrolling in Enhance, making it difficult to show a difference between the two arms of the trial.” (more…) Drugmakers Spend Lavishly On Docs Down Under Posted: 28 Mar 2008 07:15 AM CDT Australian drug companies forked out more than $30 million in six months hosting doctors at controversial events, The Sydney Morning Herald reports. Medicines Australia, the industry trade group, has been forced to detail spending on doctor seminars of up to $2,500 a head, often hosted at expensive hotels and in exotic locations. A report prepared for Medicines Australia by international consulting firm Deloitte shows that 42 companies spent $31 million, including $16.4 million on direct hospitality costs like meals, flights and hotels, in the second half of last year. In one case, AstraZeneca paid $514,000 to host a national symposium for 226 in Melbourne - a cost of $2,275 a head. There were 385,221 attendances by doctors at 14,643 functions over the period. Of these, 52 unidentified events are now under investigation for possible breaches of the new strict code of conduct, imposed by the Australian Competition and Consumer Commission to improve transparency. Want to see which drugmaker spent how much? Look at the list…. (more…) Trial Of Former Bristol-Myers CFO Is Delayed Posted: 28 Mar 2008 06:34 AM CDT Frederick Schiff, who faces two felony counts of conspiracy and securities fraud for his role in an alleged channel stuffing scheme to inflate the earnings between 2002 and 2002, just got his second break in as many weeks. You may recall that last week, US District Court Judge Faith Hochberg issued a ruling that scaled back the federal case. And so the US Attorney in Newark, NJ, Christopher Christie, has decided to appeal, which will cause an unspecified delay, The New York Times reports. In a ruling dated March 19, Judge Faith Hochberg sided with Schiff and limiting the scope of what prosecutors can argue against him and criticizing them for repeatedly changing their theory of the crime they say he committed. Б=80=9CThe court will permit no further Б=80=98legal theory morphsБ=80=99 in this case,Б=80=9D the judge said, noting that the charges against Schiff had been lingering for three years, the paper writes. One part of her order prevents the prosecution from linking SchiffБ=80=99s activities to a plunge in the price of Bristol-Myers Squibb stock during 2002, after inventory problems were disclosed. The prosecutors had hoped to use that approach to tie SchiffБ=80=99s actions to investor losses. Meanwhile, the case against Rick Lane, the former Bristol-Myers pharma head, will remain in limbo since the cases are being tried separately. (more…) New Antipsychotics No Better For First Episodes Posted: 28 Mar 2008 06:23 AM CDT The so-called atypicals - including Abilify, Risperdal, Zyprexa, Seroquel and Geodon - have been hailed as more effective and easier to tolerate than the older and cheaper kind such as Haldol, which cause tremors and rigid muscles. But the new generation are no better at treating a first episode of schizophrenia, according to a study in The Lancet. Such findings are important because the atypicals are heavily promoted, widely prescribed and expensive. The Dutch researchers studied 498 patients between 18 and 40 years old in Europe and Israel in an open trial lasting 12 months. The patients were randomly assigned to a low-dose version of Haldol, or a higher dose of one of four atypicals. They found that during the subsequent 12-month period, more patients taking Haldol discontinued treatment when compared with patients taking the other drugs. However, the reductions in all symptoms were about the same for all groups. But when the researchers further analyzed the data according to sex, tendencies towards suicide, and substance abuse, they found no significant differences between the drugs. Despite a high continuation rate for several of the atypicals, the researchers wrote that “it cannot be concluded that antipsychotic drugs are more efficacious in the treatment of these As an aside, many of the authors reported various ties to the drugmakers that sell atypicals. And funding for the study was provided by AstraZeneca, Pfizer and Sanofi-Aventis. Up And Down The Ladder… Job Changes Posted: 28 Mar 2008 06:13 AM CDT Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and weБ=80=99ll share with it others. ThatБ=80=99s right. Send us your announcements and weБ=80=99ll find a home for them. DonБ=80=99t be shy. Everyone wants to know who is coming and going, especially with all the layoffs being announced each month. Despite downsizing, there is movement. Here are some of the latest changes. Recognize anyone? Depomed hired Abid Rawn as vp sales and marketing; Regeneron promoted Joanne Deyo to vp facilities; EKR Therapeutics named Richard DeSimone as COO; EKR Therapeutics hired Ernic Biczak as senior vp marketing; EKR Therapeutics hired Dave Iwanicki as senior vp commercial operations; EKR Therapeutics hired Stephen Hulse as vp sales; EKR Therapeutics promoted Tong Zhang to vp business development; Cornerstone BioPharma named George Esgro vp sales and marketing; Xencor appointed David King as chairman; BioMarin Pharma hired Steve Glass as vp and general mgr of European operations; Zelos Therapeutics named David Krause as senior vp R&D and chief medical officer; Biovitrium hired Peter Edman as chief scientific officer from AstraZeneca, where he was vp global development; MPM Capital hired Robert Millman as chief IP counsel from Alnylam MPM Capital also hired Elizabeth Stoner from Merck Research Labs; Takeda named Alan MacKenzie as ceo of Takeda Pharma North America; Takeda also named Nancy Joseph-Ridge as president of Takeda global R&D center; Barr Labs named Christine Mundkur chief exec of the generic unit; Barr Labs also named G. Frederick Wilson chief exec of the Duramed unit; Barr Labs named Mike Bogda president and COO; And Barr Labs named Tim Sawyer exec vp of global generic sales and marketing. It’s Friday! Posted: 28 Mar 2008 06:10 AM CDT We are particularly happy, especially after our difficulties yesterday. You may have noticed sporadic posting, which was due to a burst pipe valve in the basement of the Pharmalot headquarters, a disruption assuaged only by our on-call Pharmalot maintenance crew. The problem has been solved, although we look forward to a respite. Nonetheless, there is much to do, especially as the American College of Cardiology conference kicks off and we prepare for a speaking engagement of our own. So grab that cup of stimulation and polish off the week with us… Drug-Coated Stents No Riskier Than Others: Study (Dow Jones) Some Biotechs Race To Develop Biosimilars (Bloomberg News) J&J Foot Gel Poses Cancer Risk (Yahoo/Reuters) Takeda Scraps Development Of Cholesterol Pill (Bloomberg News) Wyeth And Trubion Halt Drug Study (The Seattle Skye Pharma Seeks Compromise On Its Bonds (The Financial Times*) * - subscription may be required Death Of A Sales Team? Wyeth Cuts 1,200 Reps Posted: 27 Mar 2008 08:00 PM CDT The positions are being eliminated as of Monday as part of a major companywide program announced two months ago to save money in the face of regulatory setbacks and generic competition. At the time, the drugmaker acknowledged plans to cut about 10 percent of its global workforce of 50,000 or so, and that sales reps were high on the list. Wyeth employs roughly 25,000 people in the US. A Wyeth spokesman tells the Associated Press that reps will be cut from both the pharma and consumer products divisions from around the US. etkus said they will get severance pay and continuing benefits. He would not say how many US sales reps Wyeth employs, although one source say the primary care sales force numbers fewer than 2,000. The drugmaker has been whittling away at its sales teams since 2005, when it cut about 20 percent of its reps and began using more part-timers. For now, the spokesman says the number of overall jobs to be shed as part of the ongoing reorganization may change. still evaluating the composition of our global work force,” he told the AP. “Our short-term objective is to achieve a reduction in force of 4 to 6 percent by the middle of the year. We are on track to achieve that.” Last month, Wyeth won FDA approval to sell its Pristiq antidepressant, but the drugmaker has otherwise run into one setback after another in winning permission to market other drugs. Over the past year, the FDA has bounced a drug, demanded more data or a new patient study. Meanwhile, Wyeth expects generic competition for the Protonix heartburn med, one of its biggest sellers with sales of $1.9 billion. Japanese Drugmaker Pays $4M To Settle Fraud Posted: 27 Mar 2008 04:58 PM CDT Otsuka American Pharmaceutical, the US unit of the Japanese drugmaker, agreed to pay more than $4 million to resolve allegations that it marketed the Abilify antipsychotic for off-label uses, according to the US Department of Justice. The settlement resolves allegations that, from 2002 through 2005, Otsuka knowingly promoted the sale and use of Abilify for pediatric use and to treat psychosis, although at the time, the FDA had not approved the drug for use in geriatric patients, teenagers or children. Last November, the FDA did approve Abilify for teenagers. Otsuka developed Abilify in Japan and then entered an agreement with Bristol-Myers to co-promote the drug in the US. Bristol-Myers paid $515 million last September to settle the same allegations. Meanwhile, the whistleblower, Joseph Piacentile, a physician, will receive about $348,000 as his share of the federal recovery amount from the settlement, and an additional share of the state settlement amount. You are buy onlined to email updates from Pharmalot To stop receiving these emails, you may purchase now.Email Delivery powered by FeedBurner Inbox too full? Buy online to the feed version of Pharmalot in a feed reader. If you prefer to purchase via postal mail, write to: Pharmalot, c/o FeedBurner, 20 W Kinzie, 9th Floor, Chicago IL USA 60610

... Back to listing 24

... Back to article 4640 | SITEMAP | Next to article 4642 ...

We would like to express our gratitude to all those who are kindly providing this unique content, especially to:

office@a3ides.com
olga@bemobile.md
tirlik@brainchildhunter.com
office@bemobile.md
sharuha@causeni.info
info@webconsulting.md
irina.gorea@bemobile.md
office@milieukontakt.nl
igor.romanyuk@bemobile.com.ua
yuri.sekretar@olympia.net.ua
info@tophost.md
webmoldova@yahoo.com
admin@bemobile.md
webmaster@bemobile.md
emil@a3ides.com
olea@bemobile.md
yuri.sekretar@bemobile.com.ua
contact@a3ides.com
info@a3ides.com
vitaliy.lozovskiy@bemobile.md
drugg83@yahoo.com
rector@usm.md
gaugash@usm.md
acad.rudic@mail.md
acadrudic@yahoo.com
veaceslav.vasilache@gmail.com
s.bakker@milieukontakt.nl
katea.melnicenco@gmail.com
mkoe.moldova@vox.md
musteata@doctor.com
renat.buga@ase.md
s.molenkamp@milieukontakt.nl
si_problemme@mail.ru
willem.tjebbe.oostenbrink@planet.nl

Tag cloud:

Posted:, percent, drugmaker, Therapeutics, million, between, Pharmalot, Bristol-Myers, although, Abilify, patients, generic, treatment, doctors, American, according, especially, researchers, marketing;, Meanwhile,, against, including, scientific, promoted, College, Cardiology, conference, results, president, Capital,

Similar listing on: